Literature DB >> 10633468

Low bone turnover in patients with renal failure.

M M Couttenye1, P C D'Haese, W J Verschoren, G J Behets, I Schrooten, M E De Broe.   

Abstract

Renal failure inevitably leads to metabolic bone disease. Low turnover disease or adynamic bone disease (ABD) is characterized by a low number of osteoblasts with normal or reduced numbers of osteoclasts. Mineralization proceeds at a normal rate, resulting in normal or decreased osteoid thickness. Recently, it became clear that the relative contribution of the various types of renal osteodystrophy (ROD) to the spectrum of the histologic picture in renal failure patients underwent profound changes during the last 25 years. At the moment, the exact physiopathological mechanisms behind ABD are not yet elucidated, and thus the reason(s) for its increasing prevalence remains poorly understood. A number of epidemiological and experimental data suggest a multifactorial pathophysiologic process, in which hypoparathyroidism and suppression of the osteoblast are the main actors. Compared to adynamic bone disease, osteomalacia has now become a much rarer disease (around 4%), at least in Western countries. On the other hand, recent studies indicate that this particular bone disease entity might still regularly occur in less developed countries. Osteomalacia originates from a direct effect on the mineralization process. With this type of renal bone disease, the effects of secondary hyperparathyroidism on bone are overridden by a number of metabolic abnormalities that finally result in a defective bone mineralization, as occurs, for instance, when the lag time between osteoid deposition and its mineralization is increased. The relationship between exogenous and endogenous vitamin D deficiency (mainly calcitriol) and the histologic finding of osteomalacia in uremic patients is well known. Recent data showed distinctly lowered 25-(OH) vitamin D3 levels in the presence of unaffected calcitriol concentrations in patients with osteomalacic lesions, as assessed radiologically by the presence of Looser's zones. Recently, we found that bone strontium levels were increased in patients with osteomalacia as compared to all other types of ROD. Strontium accumulation appeared to originate mainly from the use of strontium-contaminated dialysate, which resulted from the addition of strontium-containing acetate-based concentrates. Evidence for a causal role of the element in the development of a mineralization defect could be tested experimentally by adding strontium to drinking water in a chronic renal failure rat model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10633468     DOI: 10.1046/j.1523-1755.1999.07308.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  13 in total

Review 1.  Renal osteodystrophy.

Authors:  E A González; K J Martin
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

2.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

3.  Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.

Authors:  Hartmut H Malluche; Hanna W Mawad; Marie-Claude Monier-Faugere
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

4.  Effects of Na/K-ATPase and its ligands on bone marrow stromal cell differentiation.

Authors:  Moustafa Sayed; Christopher A Drummond; Kaleigh L Evans; Steven T Haller; Jiang Liu; Zijian Xie; Jiang Tian
Journal:  Stem Cell Res       Date:  2014-04-13       Impact factor: 2.020

5.  Bone histomorphometry in a long-term hemodialysis patient with hypoparathyroidism and sarcoidosis.

Authors:  K Sumida; Y Ubara; J Hoshino; N Hayami; T Suwabe; R Hiramatsu; E Hasegawa; M Yamanouchi; N Sawa; T Fujii; K Takaichi
Journal:  Osteoporos Int       Date:  2014-12-13       Impact factor: 4.507

6.  Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease?

Authors:  Mingxin Wei; Khaled Esbaei; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

7.  CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy.

Authors:  Feng-Xiang Yan; M Chris Langub; Mark A Ihnen; Carlton Hornung; Erkki Juronen; Mary K Rayens; Wei-Min Cai; Peter J Wedlund; Paolo Fanti
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

8.  Adynamic bone disease-bone and beyond.

Authors:  Vincent M Brandenburg; Jürgen Floege
Journal:  NDT Plus       Date:  2008-06

9.  Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.

Authors:  Min Seok Cho; Kyun Sang Lee; Youn Kyoung Lee; Seong Kwon Ma; Jeong Hee Ko; Soo Wan Kim; Nam Ho Kim; Ki Chul Choi
Journal:  Korean J Intern Med       Date:  2002-06       Impact factor: 2.884

10.  Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?

Authors:  Juliana C Ferreira; Guaraciaba O Ferrari; Katia R Neves; Raquel T Cavallari; Wagner V Dominguez; Luciene M Dos Reis; Fabiana G Graciolli; Elizabeth C Oliveira; Shiguang Liu; Yves Sabbagh; Vanda Jorgetti; Susan Schiavi; Rosa M A Moysés
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.